Prevest Denpro

Why is Prevest Denpro Ltd falling/rising?

As of 04-Aug, Prevest Denpro Ltd's stock price is declining, currently at 384.05, reflecting a significant underperformance compared to the Sensex and a decrease in investor interest. The stock's persistent downward trend, poor long-term growth metrics, and high valuation concerns are contributing to its falling price.

As of 04-Aug, Prevest Denpro Ltd's stock price is falling, currently at 384.05, which reflects a decrease of 13.2 or 3.32%. The stock has underperformed significantly compared to the benchmark Sensex, which has gained 2.17% over the past week while Prevest Denpro has declined by 1.69%. Over the past month, the stock has also seen a decrease of 1.97%, contrasting with the Sensex's modest gain of 0.86%.<BR><BR>The stock has been on a downward trend, having fallen consecutively for the last two days, with a total decline of 5% during this period. Today's trading saw the stock reach an intraday low of Rs 381.55, marking a decrease of 3.95%. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a persistent downward momentum.<BR><BR>Investor participation has also diminished, with delivery volume dropping by 47.37% compared to the 5-day average, suggesting reduced interest from investors. The stock's liquidity is adequate for trading, but the overall sentiment appears negative.<BR><BR>Moreover, the company has shown poor long-term growth, with net sales increasing at an annual rate of only 12.85% and operating profit at 7.55% over the last five years. The recent financial results have been flat, with the return on capital employed (ROCE) at its lowest and a low inventory turnover ratio. Although the company is net-debt free and has a high return on equity (ROE) of 16.81%, its valuation remains expensive with a price-to-book ratio of 3.7, contributing to the stock's decline.<BR><BR>In summary, the combination of underperformance against benchmarks, declining investor interest, poor long-term growth metrics, and high valuation concerns are contributing to the falling stock price of Prevest Denpro Ltd.

Which are the latest news on Prevest Denpro?

What does Prevest Denpro do?

Prevest Denpro Ltd is a micro-cap manufacturer of dental materials, incorporated in 1999, with recent net sales of 19 Cr and a net profit of 6 Cr as of March 2026. The company has a market cap of INR 460 Cr and key financial metrics include a P/E ratio of 22.00 and a return on equity of 16.42%.

Overview:<BR>Prevest Denpro Ltd is a leading manufacturer of dental materials in the healthcare services industry, categorized as a micro-cap company.<BR><BR>History:<BR>The company was incorporated on May 05, 1999, with the Registrar of Companies in Jammu & Kashmir. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 19 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 6 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 460 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 22.00 <BR>Industry P/E: 92 <BR>Dividend Yield: 0.27% <BR>Debt Equity: -0.65 <BR>Return on Equity: 16.42% <BR>Price to Book: 3.54 <BR><BR>Contact Details:<BR>No Company Details Available <BR>Registrar Address: Not available.

How big is Prevest Denpro?

As of 10th June, Prevest Denpro Ltd has a market capitalization of 460.00 Cr and reported net sales of 71.81 Cr and net profit of 20.49 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Prevest Denpro Ltd has a market capitalization of 460.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 71.81 Cr, while the sum of Net Profit for the same period is 20.49 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 105.57 Cr, and Total Assets amount to 112.53 Cr.

Who are in the management team of Prevest Denpro?

The management team of Prevest Denpro includes Atul Modi (Chairman & Managing Director), Namrata Modi (Whole Time Director & CFO), Sai Kalyan Surapaneni (Executive Director), Niharika Modi (Non-Executive Director), Nikhil Shrikant Bobade (Independent Non-Executive Director), Sudeep Haralakatte Murthy (Independent Non-Executive Director), Vaibhav Munjal (Executive Director), and Pardeep Gandotra (Independent Non-Executive Director). They oversee the company's operations and strategic direction.

The management team of Prevest Denpro includes the following individuals:<BR><BR>1. **Atul Modi** - Chairman & Managing Director<BR>2. **Namrata Modi** - Whole Time Director & CFO<BR>3. **Sai Kalyan Surapaneni** - Executive Director<BR>4. **Niharika Modi** - Non-Executive Director<BR>5. **Nikhil Shrikant Bobade** - Independent Non-Executive Director<BR>6. **Sudeep Haralakatte Murthy** - Independent Non-Executive Director<BR>7. **Vaibhav Munjal** - Executive Director<BR>8. **Pardeep Gandotra** - Independent Non-Executive Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Who are the peers of the Prevest Denpro?

Prevest Denpro's peers include 3B Blackbio, Health X Platfor, Hemant Surgical, Take Solutions, Nureca, Jeevan Scientific, and QMS Medical. Hemant Surgical leads in 1-year returns at 278.57%, while 3B Blackbio has the lowest at -23.84%, with Prevest Denpro slightly better at -22.92%.

Peers: The peers of Prevest Denpro are 3B Blackbio, Health X Platfor, Hemant Surgical, Take Solutions, Nureca, Jeevan Scienti., and QMS Medical.<BR><BR>Quality Snapshot: Excellent management risk is observed at 3B Blackbio and Health X Platfor, while Average management risk is found at Hemant Surgical and QMS Medical, and the rest have Below Average management risk. Growth is Good at Hemant Surgical, Average at Health X Platfor, and Below Average at 3B Blackbio, Take Solutions, Nureca, Jeevan Scienti., and QMS Medical. Excellent capital structure is noted for 3B Blackbio and Health X Platfor, Good for Nureca and Hemant Surgical, while Average is seen at Jeevan Scienti. and QMS Medical, and Below Average at Take Solutions.<BR><BR>Return Snapshot: Hemant Surgical has the highest 1-year return at 278.57%, while 3B Blackbio has the lowest at -23.84%, with Prevest Denpro's 1-year return at -22.92%, indicating it is slightly better than 3B Blackbio. Additionally, the six-month returns for 3B Blackbio, Health X Platfor, Take Solutions, Nureca, and QMS Medical are all negative.

Should I buy, sell or hold Prevest Denpro Ltd?

When is the next results date for Prevest Denpro Ltd?

The next results date for Prevest Denpro Ltd is 27 May 2026.

The next results date for Prevest Denpro Ltd is scheduled for 27 May 2026.

Are Prevest Denpro Ltd latest results good or bad?

Prevest Denpro Ltd's Q2 FY26 results are positive, with a net profit of ₹5.54 crores, reflecting a 25.62% QoQ increase and an 18.20% rise in revenue. The company shows strong operational efficiency, but investors should be cautious of declining capital efficiency and stretched valuations.

Prevest Denpro Ltd's latest results for Q2 FY26 are quite positive. The company reported a net profit of ₹5.54 crores, which reflects a significant increase of 25.62% quarter-on-quarter (QoQ) and 14.94% year-on-year (YoY). Additionally, revenue reached ₹18.64 crores, marking an 18.20% increase QoQ and a healthy 14.57% YoY growth. <BR><BR>The operating margin also improved to 35.84%, up 211 basis points from the previous quarter, indicating effective cost management despite rising raw material and employee costs. The company's profit after tax margin expanded to 29.72%, further showcasing improved operational efficiency.<BR><BR>Overall, these results indicate strong operational momentum and profitability, positioning Prevest Denpro favorably within its sector. However, it's important to monitor the declining capital efficiency and the company's valuation, which appears stretched relative to its growth prospects.

Is Prevest Denpro overvalued or undervalued?

As of December 3, 2025, Prevest Denpro is considered overvalued with a valuation grade of expensive, a PE ratio of 27.29, and a year-to-date return of -24.41%, underperforming against the Sensex's 8.92%.

As of 3 December 2025, the valuation grade for Prevest Denpro has moved from very expensive to expensive. The company is currently considered overvalued. Key ratios include a PE Ratio of 27.29, an EV to EBITDA of 19.44, and a Price to Book Value of 4.63. <BR><BR>In comparison to peers, Prevest Denpro's PE ratio is lower than that of Poly Medicure, which stands at 53.52, but higher than BPL, which is at 5.92. The PEG ratio of Prevest Denpro is 1.47, indicating that while growth is priced in, it does not justify the current valuation when compared to its peers. Additionally, the company's stock has underperformed against the Sensex, with a year-to-date return of -24.41% compared to the Sensex's 8.92%.

How has been the historical performance of Prevest Denpro?

Prevest Denpro's historical performance from March 2024 to March 2025 shows growth in net sales to 63.03 Cr, operating profit to 26.16 Cr, and profit after tax to 18.16 Cr, alongside an increase in cash reserves to 60.00 Cr, indicating overall positive financial trends.

Answer:<BR>The historical performance of Prevest Denpro shows a positive trend in key financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Prevest Denpro reported net sales of 63.03 Cr, an increase from 56.43 Cr in the previous year. The total operating income also rose to 63.03 Cr from 56.43 Cr, with raw material costs slightly increasing to 14.08 Cr from 13.76 Cr. Total expenditure, excluding depreciation, grew to 40.94 Cr from 36.58 Cr, leading to an operating profit (PBDIT) of 26.16 Cr, up from 22.71 Cr. Profit before tax increased to 24.25 Cr from 21.43 Cr, resulting in a profit after tax of 18.16 Cr, compared to 16.14 Cr the previous year. The earnings per share improved to 15.13 from 13.45, while the operating profit margin slightly decreased to 35.05% from 35.18%. The profit after tax margin increased to 28.81% from 28.6%. On the balance sheet, shareholder's funds rose to 105.57 Cr from 88.62 Cr, with total assets increasing to 112.53 Cr from 94.82 Cr. Cash and cash equivalents at year-end improved to 60.00 Cr from 48.00 Cr, indicating a net cash inflow of 12.00 Cr compared to 9.00 Cr in the prior year. Overall, the financial performance of Prevest Denpro reflects growth in sales, profits, and cash reserves.

Is Prevest Denpro technically bullish or bearish?

As of November 7, 2025, the technical trend is mildly bearish, supported by bearish signals from the MACD, Dow Theory, and Bollinger Bands, despite a mildly bullish daily moving average.

As of 7 November 2025, the technical trend has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the weekly and monthly MACD and Dow Theory indicators, both indicating a bearish outlook. The Bollinger Bands also reflect a bearish sentiment on both weekly and monthly time frames. Although the daily moving averages show a mildly bullish signal, this is overshadowed by the overall bearish indicators. The stock has underperformed against the Sensex over multiple periods, further supporting the bearish view.

Who are the top shareholders of the Prevest Denpro?

The top shareholders of Prevest Denpro include Atul Modi, the largest individual shareholder with 37.52%, and a foreign institutional investor holding 0.63%. Public shareholders include Pushpa Kumari Pankaj Prasoon at 2.47%, while individual investors collectively hold 19.54%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Prevest Denpro include the promoters, with Atul Modi being the largest individual shareholder, holding 37.52% of the shares. Additionally, there is one foreign institutional investor (FII) that holds 0.63% of the shares. Among public shareholders, Pushpa Kumari Pankaj Prasoon is the highest, with a holding of 2.47%. Individual investors collectively hold 19.54% of the company. There are no pledged promoter holdings and no mutual funds currently invested in the company.

Has Prevest Denpro declared dividend?

Prevest Denpro Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of August 30, 2024. While the company shows mixed total returns across different periods, the dividend yield is relatively low at 0.21%.

Prevest Denpro Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 30 Aug 2024<BR><BR>Dividend Yield: 0.21%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -13.05%, with a dividend return of 0%, resulting in a total return of -13.05%.<BR><BR>Over the past year, the price return was 25.21%, the dividend return was 0.23%, leading to a total return of 25.44%.<BR><BR>In the 2-year period, the price return was 16.99%, the dividend return was 0.47%, culminating in a total return of 17.46%.<BR><BR>For the 3-year period, the price return stood at 60.7%, with a dividend return of 0.72%, resulting in a total return of 61.42%.<BR><BR>Over the last 4 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>In the 5-year period, both the price return and dividend return were 0%, resulting in a total return of 0.0%.<BR><BR>Overall, while Prevest Denpro has declared a dividend, the total returns over various periods show a mixed performance, with significant gains in the longer term but recent declines in the short term. The dividend yield remains relatively low, indicating that while dividends are being paid, they may not be a significant driver of returns for investors.